drugset
drugset / Trial / NCT06585774

A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

NCT06585774 ↗

Phase 3 Recruiting 240 enrolled Incyte Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will be conducted to compare the efficacy of axatilimab versus placebo in combination with corticosteroids as initial treatment for moderate or severe chronic graft-versus-host disease (cGVHD).

Timeline

Start
2025-01-21
Primary completion
2027-09-28
Completion
2030-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Axatilimab Monoclonal antibody — Intravenous
Background Methylprednisolone Other / unclassified — Oral
Background Prednisolone Other / unclassified — Oral
Background Prednisone Other / unclassified — Oral

Indications

chronic graft versus host disease